Johnson Investment Counsel Inc. Acquires 1,736 Shares of Sanofi $SNY

Johnson Investment Counsel Inc. increased its holdings in shares of Sanofi (NASDAQ:SNY) by 14.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,832 shares of the company’s stock after buying an additional 1,736 shares during the period. Johnson Investment Counsel Inc.’s holdings in Sanofi were worth $668,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of SNY. Brighton Jones LLC raised its stake in shares of Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock worth $261,000 after buying an additional 1,869 shares during the last quarter. Farther Finance Advisors LLC increased its stake in shares of Sanofi by 66.2% in the 1st quarter. Farther Finance Advisors LLC now owns 6,215 shares of the company’s stock valued at $338,000 after acquiring an additional 2,476 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Sanofi by 58.7% in the 1st quarter. GAMMA Investing LLC now owns 6,057 shares of the company’s stock valued at $336,000 after acquiring an additional 2,241 shares during the last quarter. Janney Montgomery Scott LLC increased its stake in shares of Sanofi by 3.6% in the 1st quarter. Janney Montgomery Scott LLC now owns 339,437 shares of the company’s stock valued at $18,825,000 after acquiring an additional 11,806 shares during the last quarter. Finally, Sowell Financial Services LLC bought a new stake in shares of Sanofi in the 1st quarter valued at about $328,000. 14.04% of the stock is owned by institutional investors.

Sanofi Price Performance

NASDAQ SNY opened at $49.22 on Wednesday. Sanofi has a 52-week low of $44.62 and a 52-week high of $60.12. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. The business has a 50 day simple moving average of $48.32 and a 200 day simple moving average of $49.70. The stock has a market cap of $120.86 billion, a price-to-earnings ratio of 11.83, a PEG ratio of 1.19 and a beta of 0.51.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The firm had revenue of $11.34 billion for the quarter, compared to analyst estimates of $9.91 billion. During the same period last year, the company earned $1.73 EPS. The company’s revenue was down 7.0% compared to the same quarter last year. Analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Barclays reaffirmed an “overweight” rating on shares of Sanofi in a research note on Wednesday, July 2nd. JPMorgan Chase & Co. raised Sanofi from a “neutral” rating to an “overweight” rating in a research note on Friday, August 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Sanofi in a research note on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Finally, Morgan Stanley raised Sanofi from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $56.00 to $58.00 in a research note on Monday, September 8th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $62.67.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.